Tips For Growing Your Practice In The New Normal

If recent times have seen an underlying constant, it’s the somber numbers/reports, and the fact that old rules simply don’t cut it anymore. The same applies to the process of growing your physician practice, regardless of whether you’re building it from scratch or simply trying to expand your business.

In an effort to streamline the process and outline a clear course of action, a survey was done with 2005 respondents spread out across 5 regions of the US. The numbers paint a clear picture: 69% of the respondents postponed healthcare services, while 82% of them came across difficulties with scheduling appointments!

Article Growing Your Practice

The survey is presented in a neat infographic that outlines the crucial percentages and considerations. It illustrates the point that health care providers now have the chance to adapt and overcome, both as practicing physicians and as business owners. Regardless of whether it’s time to do your own research about your patient pool preferences or learn more about scheduling software, the numbers in the infographic provide you with a good starting point to begin boosting your patient flow.

The opportunity to grow and expand comes in many forms. One of those is updating and customizing your booking procedure – tweak it according to demographic preferences, be that age groups or any other distinguishing factor. Another consideration is staying on top of trends when it comes to patients choosing their health care service provider – keep your eyes on the ball to see where your client base is moving, and try to get there before to welcome them.

The pandemic has switched things around for a lot of industries, but none more so than health care. This makes perfect sense since health care took the brunt of the hit, and shouldered it right through a very confusing two-year period. However, now it’s time to recuperate, to take the lessons we were forced to learn quickly along the way, and apply them to our daily tasks.

 

 

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”